Can Chinese Test Reports Be Reused for Medical Device Registration in Thailand?

Existing NMPA test reports and technical documentation can serve as a basis for a Thai medical device registration, but in most cases they cannot be submitted as-is. Thai medical device registration (Thai FDA) typically requires first confirming the product classification and applicable registration pathway, then preparing technical files, labels and instructions for use, quality management system evidence, authorization documents and local representative materials. NMPA data may be usable, but it usually needs to be adapted for language, format, labelling and evidence-chain requirements under Thai regulations. For Chinese medical device manufacturers, the most reliable approach is to complete a product classification and documentation gap assessment first, and only then determine whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused. Thai registration generally affects technical files, authorized representation, importer cooperation, label language, QMS evidence and subsequent change maintenance at the same time; if a project is driven only by a list of documents to be submitted, corrections or rework are likely to arise in model coverage, evidence-chain consistency, labelling claims and certificate control.

Article Information

Published: 10 July 2026, 12:04
Last updated: 10 July 2026, 12:04

This article addresses the questions companies most often need to resolve first in practice, covering international medical device registration, documentation preparation, compliance pathways and post-market maintenance.

Key Takeaways

• Thai medical device registration usually begins with confirming the product classification and applicable pathway before technical files, labels and instructions for use, QMS evidence, authorization documents and local representative materials are prepared.
• Existing NMPA documentation can be used as a foundation, but normally requires adaptation for language, format, labelling and evidence-chain requirements under Thai FDA rules.
• For Chinese manufacturers, the safer route is to complete a product classification and documentation gap assessment first, then decide whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused.
• Thai registration typically affects technical files, authorized representation, importer cooperation, label language, QMS evidence and ongoing change maintenance at the same time.
• Rather than rebuilding documentation country by country, companies are advised to plan this question within a GHWP member state and multi-country market access strategy, using one reusable core technical file to support localization in different markets.
• Judgements should be project-specific, taking into account the latest requirements of the target regulator, the existing technical file basis, the product risk class and the launch plan, rather than mechanically following a documentation checklist.

Applicable Scenarios and Core Questions

Companies searching for whether test reports from a Chinese medical device registration can be reused in Thailand are usually not looking for a conceptual explanation. They want to know whether their existing documentation can support a Thai submission, whether a local agent or authorized representative is required, why timelines are extended, and which issues could affect the launch plan. Behind this question there are usually several linked topics: product classification, registration pathway, evidence chain, label localization and post-market maintenance responsibilities.

If a company plans to enter several GHWP member states or markets in Southeast Asia, the Middle East and Latin America at the same time, a country-by-country answer is not sufficient. A more valuable approach is to first develop reusable versions of the core technical file, QMS evidence, performance verification, clinical evidence and labels and instructions for use, and then localize them according to each country's regulatory requirements.

Registration Assessment Logic

Companies should first confirm the intended use, mechanism of action, usage scenario, mode of body contact, duration of use, whether the device is sterile, whether it is powered, and whether it incorporates software or has IVD characteristics. Only then should the risk class and submission pathway be determined. If the pathway is assessed incorrectly, all subsequent translation, notarization, authorization, testing and supplementary documentation will move in the wrong direction.

For a Thai project, it is also necessary to define the applicant entity and the local responsibility boundaries: who holds the certificate, who handles regulatory communication, who manages import and post-market events, who triggers changes, and who maintains documentation for renewal. If these matters are left vague in commercial contracts, market control can easily be affected later.

Documentation and Evidence

Typical documentation includes the product description, model and specification matrix, intended use, risk classification rationale, ISO 13485 or applicable QMS evidence, technical file, performance verification reports, risk management file, clinical evaluation or clinical evidence, labels and instructions for use, authorization documents, existing registration certificates, manufacturer declarations and post-market surveillance documentation.

The key to documentation quality is not quantity but consistency. IFU claims, the models covered by test reports, the scope of clinical evidence, risk management conclusions, label warnings and the information in the registration application form must support one another. Regulators focus on whether the device is safe, effective and traceable for its intended purpose in the target market, not on how many documents a company has uploaded.

Common Pitfalls

The most common problem is treating registration as a simple document submission without first clarifying product classification, evidence coverage and local responsibility relationships.

• Submitting translated NMPA documentation directly without restructuring the evidence according to the Thai pathway.
• Including too many models and specifications while test reports, clinical evidence or labels do not adequately cover them.
• Selecting a local agent purely on the basis of sales cooperation, without clarifying regulatory responsibilities, certificate control and post-market maintenance obligations.
• Inconsistencies between labels, IFUs, promotional materials and registration documentation, leading to deficiency letters or post-market compliance risk.
• Failing to plan for multi-country documentation reuse in advance, so that files are rebuilt for each country and both cost and timelines are amplified.

Company Preparation Checklist

Before starting a project, companies are advised to use an internal checklist to confirm the documentation basis, so that critical evidence gaps are not discovered only after submission.

• Compile the target product list, model and specification matrix and intended use statements.
• Verify whether existing NMPA, CE, FDA or other market registration documentation can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management file, clinical evaluation and English-language IFUs.
• Confirm the responsibilities, fees, certificate control and exit mechanisms of the local agent or authorized representative.
• Establish a target-country gap assessment table specifying what requires additional testing, translation, notarization or supplementary declarations.

AIMEILI Perspective

AIMEILI advises companies not to treat Thai registration as a one-off document submission, but to manage it as an overseas market access programme. For companies preparing to enter multiple countries, building a clear core technical file and evidence matrix first and then converting it for each national requirement is usually faster, more stable and more conducive to later changes and renewals than assembling documentation on an ad hoc basis for each country.

From a project management perspective, three things should be controlled in advance: first, product classification and pathway assessment; second, consistency of the documentation evidence chain; and third, the regulatory responsibility boundaries of local partners. If these three items are unclear, the project may still encounter repeated issues during deficiency responses, agent communication and post-market maintenance, even if the documentation appears extensive.

Frequently Asked Follow-up Questions

Can Chinese domestic documentation be used directly for Thai registration?

Chinese domestic documentation can be used as a basis, but it generally cannot be submitted unchanged. Companies need to adjust the document structure, language, labelling, authorization documents and evidence chain in accordance with local regulatory requirements.

When is the best time to start a gap assessment?

It is advisable to start immediately after the target markets and product list are confirmed. The earlier the gap assessment is completed, the easier it is to arrange additional testing, translation, label adaptation and agent selection in advance.

Why does the choice of local agent affect registration quality?

Local agents typically participate in registration communication, changes, renewals and post-market event handling. Unclear responsibilities can affect certificate control and subsequent market stability.

Quality System and Evidence Consistency

From a registration review perspective, QMS documentation is not an isolated certificate. Regulators usually examine whether the manufacturer name, manufacturing address, product scope, certificate validity period, applicable standards and technical file are consistent with one another. If the scope covered by the ISO 13485 certificate does not match the product being submitted, or if the manufacturing address, model specifications and IFU version do not align with the test reports, the company may be asked for supplementary explanations even if a large volume of documentation has been prepared.

Companies should establish an evidence consistency checklist before submission, mapping the product name, model and specification, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label and IFU version, and QMS certificate item by item. This may appear basic, but it can significantly reduce the likelihood of deficiency letters, particularly for projects submitted simultaneously in multiple GHWP member states or for multiple product families.

Localization and Agent Responsibilities

Thai registration projects typically involve arrangements with a local agent, authorized representative, importer or registration holder. Companies should confirm in advance whether the local partner is responsible only for submitting documents, or also for regulatory communication, certificate maintenance, post-market event reporting, change applications and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labels, IFUs and authorization documents also cannot simply be translated. Companies should verify local language requirements, the boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information and after-sales contact details. For companies that already hold CE, FDA, NMPA or other market documentation, the focus of localization is converting reusable evidence into a submission structure acceptable in the target country, rather than drafting a separate set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Registration is not the end of compliance work. Companies must also maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions and regulatory update records. Many companies invest heavily in obtaining the certificate but neglect post-market maintenance; when a manufacturing address change, model expansion, IFU update or agent replacement subsequently occurs, the certificate and commercial sales can easily become disconnected.

AIMEILI recommends managing this topic within an annual international registration plan: define target market priorities first, then build a reusable documentation package and country gap list, and finally schedule submission, deficiency response, post-market maintenance and renewal milestones. The value of this approach is not only improved efficiency in a single country, but also the development of a repeatable compliance capability for overseas expansion, reducing the cost of starting each new market from scratch.

Further Reading

• Previous: How should clinical evaluation documentation be prepared for medical device registration in Thailand?
• Next: How should an ISO 13485 certificate be used for medical device registration in Thailand?

Recommended Reading

• How should registration documentation be prepared for medical device registration in Malaysia?
• How should product classification be determined for medical device registration in Malaysia?
• How should the technical file be organized for medical device registration in Malaysia?
• How should labels and instructions for use be localized for medical device registration in Malaysia?
• How should clinical evaluation documentation be prepared for medical device registration in Malaysia?
• Can test reports be reused for medical device registration in Malaysia?

Return to the FAQ Centre | News and Updates | Contact AIMEILI

Content Review and Scope of Application

Author: AIMEILI Regulatory Editorial Team
Professional review: AIMEILI Medical Device International Registration Project Team
Sourcing principle: Priority is given to official regulatory authorities, international organizations, standards bodies and publicly available regulatory materials; industry media and project experience are used only as supporting references.
Scope of application: This article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions or legal advice.